Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

被引：0

作者：

Chari, Ajai ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Beksac, Meral ^{[3
]}

Leleu, Xavier ^{[4
,5
]}

Weisel, Katja ^{[6
]}

Richter, Joshua ^{[7
]}

Dirnberger, Franziska ^{[8
]}

Iskander, Karim ^{[8
]}

Yusuf, Akeem ^{[8
]}

Mikhael, Joseph ^{[9
]}

机构：

[1] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Gen Hosp, Athens, Greece

[3] Ankara Univ, Ankara, Turkey

[4] CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France

[5] CIC Inserm 1402, Poitiers, France

[6] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[7] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA

[8] Amgen Inc, Thousand Oaks, CA 91320 USA

[9] City Hope Canc Ctr, Translat Genom Res Inst TGen, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-191

引用

页码：S142 / S142

页数：1

共 50 条

[21] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
Yee, Andrew
Nadeem, Omar
Rosenblatt, Jacalyn
Sperling, Adam
Bianchi, Giada
Munshi, Nikhil
O'Donnell, Elizabeth
Branagan, Andrew
Avigan, David
Liegel, Jessica
Harrington, Cynthia
Agyemang, Emerentia
Lively, Kathleen
Packer, Lisette
Han, Samuel
Minsky, Cole
Riadi, Manal
Mcvey, Cailin
Donnelly, Kaleigh
Smith, Caitlin
Katzeff, Mackenna
Goguen, Amy
Horick, Nora
Richardson, Paul
Raje, Noopur
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
[22] Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
De Novellis, Danilo
Derudas, Daniele
Vincelli, Donatella
Fontana, Raffaele
Della Pepa, Roberta
Palmieri, Salvatore
Accardi, Fabrizio
Rotondo, Francesco
Morelli, Emanuela
Gigliotta, Emilia
Roccotelli, Daniela
Marano, Luana
Barone, Maria Lucia
Cetani, Giusy
Esposito, Daniela
Lazzaro, Antonio
Delle Cave, Giuseppe
Serio, Bianca
Morini, Denise
Porrazzo, Marika
Urciuoli, Eleonora
Masucci, Chiara
Fanelli, Fulvia
Rizzo, Michela
Arcamone, Manuela
Trastulli, Fabio
Rocco, Stefano
Leone, Aldo
Bianco, Rosario
Salvatore, Flavia
Idato, Aurora
Sicari, Maria
Tosi, Patrizia
Rascato, Maria Gabriella
Di Perna, Maria
Falcone, Antonietta Pia
Morello, Lucia
Carlisi, Melania
Svanera, Gino
Annunziata, Mario
Frigeri, Ferdinando
Califano, Catello
Carella, Angelo Michele
Marcacci, Gianpaolo
Pane, Fabrizio
Risitano, Antonio Maria
Giudice, Valentina
Botta, Ciro
Selleri, Carmine
EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (01) : 105 - 114
[23] AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Potluri, R.
Chen, C.
Ranjan, S.
Kumar, A.
Bhandari, H.
Davis, C.
VALUE IN HEALTH, 2019, 22 : S104 - S104
[24] COMPARATIVE EFFICACY AND SAFETY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA USING A MATCHING-ADJUSTED INDIRECT COMPARISON
Leleu, X.
Delea, T.
Guyot, P.
Moynahan, A.
Singh, E.
Tekle, C.
Lin, P.
VALUE IN HEALTH, 2022, 25 (01) : S39 - S39
[25] Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
Richardson, Paul G.
Attal, Michel
Campana, Frank
Le-Guennec, Solenn
Hui, Ai-Min
Risse, Marie-Laure
Corzo, Kathryn
Anderson, Kenneth C.
FUTURE ONCOLOGY, 2018, 14 (11) : 1035 - 1047
[26] Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naive Relapsed Multiple Myeloma
Afrough, Aimaz
Atrash, Shebli
Paul, Barry
Ouchveridze, Evguenia
Ahmed, Nausheen
Mahmoudjafari, Zahra
Bashir, Anam
Alkharabsheh, Omar
Hashmi, Hamza
Abdallah, Al-Ola
CANCERS, 2023, 15 (19)
[27] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Dimopoulos, Meletios A.
San-Miguel, Jesus
Belch, Andrew
White, Darrell
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Sutherland, Heather J.
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, H. Miles
Cochrane, Tara
Oriol, Albert
Bahlis, Nizar J.
Chari, Ajai
O'Rourke, Lisa
Wu, Kaida
Schecter, Jordan M.
Casneuf, Tineke
Chiu, Christopher
Soong, David
Sasser, A. Kate
Khokhar, Nushmia Z.
Avet-Loiseau, Herve
Usmani, Saad Z.
HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
[28] DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B- Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Trudel, Suzanne
Davis, Randy
Lewis, Nicole M.
Bakshi, Kalpana K.
Chopra, Bikramjit
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Eliason, Laurie
Kremer, Brandon E.
Gupta, Ira
Wu, Frank S.
BLOOD, 2020, 136
[29] MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
Mateos, Maria-Victoria
Bahlis, Nizar J.
Costa, Luciano J.
Perrot, Aurore
Pei, Lixia
Rubin, Maria L.
Lantz, Kristen
Sun, Weili
Jaffe, Mindy
Kobos, Rachel
Nooka, Ajay K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
Yee, Andrew J.
Nadeem, Omar
Rosenblatt, Jacalyn
Bianchi, Giada
O'Donnell, Elizabeth
Branagan, Andrew R.
Harrington, Cynthia C.
Agyemang, Emerentia A.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette A.
Bernstein, Zachary S.
Lyons, Rebecca T.
Riadi, Manal
Rowell, Sean M.
Mcvey, Cailin
Goguen, Amy C.
Horick, Nora K.
Richardson, Paul G.
Raje, Noopur S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →